#$24.54

[thequakergoesdeaf]

The Quaker Goes Deaf - Playlist 24.54

[ciochinaflorin]

270. SELECTEAZĂ CORECT 66. AMÂNAREA ESTE HOȚUL TIMPULUI [Geneza 24.54–61 I Exod 10.3, 7 I Judecători 3.23–30 I 2 Corinteni 8.11]

270. SELECTEAZĂ CORECT 66. AMÂNAREA ESTE HOȚUL TIMPULUI [Geneza 24.54–61 I Exod 10.3, 7 I Judecători 3.23–30 I 2 Corinteni 8.11]

270. SELECTEAZĂ CORECT 66. AMÂNAREA ESTE HOȚUL TIMPULUI I Podcast I Pasaje Biblice : Geneza 24 : 54 – 61 I Exod 10 : 3, 7 I Judecători 3 : 23 – 30 I 2 Corinteni 8 : 11 I Meditaţii din Cuvânt I Cezareea I Reşiţa I 27 Septembrie 2022 I Cu studiul despre neputințe și metehne am ajuns la Geneza 24 : 54 – 61 unde scrie despre Eliezer (un om în vârstă) că : (more…)

[gemville]

Platinum, 18k White Gold, 12-13.4mm South Sea Cultured Pearl and 24.54 CTW Diamond Rivière Necklace by Sean Gilson for Assael

Photo Courtesy: Sean Gilson for Assael

Source: jckonline.com

[follow-up-news]

Tesla’s second-quarter net income fell 45% compared with a year ago as the company’s global electric vehicle sales tumbled despite price cuts and low-interest financing. The Austin, Texas, company said Tuesday that it made $1.48 billion from April through June, less than the $2.7 billion it made in the same period of 2023. It was Tesla’s second-straight quarterly net income decline. Second quarter revenue rose 2% to $25.5 billion, beating Wall Street estimates of $24.54 billion, according to FactSet. Excluding one time items, Tesla made 52 cents per share, below analyst expectations of 61 cents. Earlier this month Tesla said it sold 443,956 vehicles from April through June, down 4.8% from 466,140 sold the same period a year ago. Although the sales were were better than the 436,000 that analysts had expected, they still were a sign of weakening demand for the company’s aging product lineup. For the first half of the year, Tesla has sold about 831,000 vehicles worldwide, far short of the more than 1.8 million for the full year that CEO Elon Musk has predicted.

[dyxtd21]

Iolite's Trivia

She is considered to make an important decision in someone's life.

Her height is 5'8''

She has been loved by many artists and creators (historical figures) and still is.

She gets along with Smoky Quartz, Ametrine and Parti Sapphire.

She dislikes Thulite, whose has everything dolphin motif.

Her Mohs scale number is 7.5.

She was created in the land where Norway now resides.

Her pricing is $24.54 up to $342.95.

She is closely related to Vikings who used her in order for their navigations.

Her Zodiac sign is Libra.

Before she got her name "Iolite," she was named "Cordierite" by French geologist, Pierre Cordier. Afterwards, she travelled to Greece where the people called her "Iolite" and she likes her name.

She is able to make any boy and girl fall easily in love with her.

She is able to aid in releasing the causes of addiction from others.

She has a strong sense of smell.

She has met the ancient being known as the Megalodon and was great friends with it.

Iolite is sometimes seen as a queen of shark kind.

She has two non-shark siblings: Star Iolite, a small village chieftess and Bloodshot Iolite, a vampire.

[modern-alebrije]

$24.54 at target after price-matching amazon

[beardedmrbean]

CEC data as of 5:55 p.m. with 100% of sectional protocols processed in the Regional Election Commissions show that six political formations will enter the 49th National Assembly: GERB - SDS, WCC-DB, "Vazrazhdane", DPS, BSP and " There Is Such a People".

GERB - SDS have 26.51%, or with a 1.93% lead over WCC-DP, which received 24.54% of the votes. The difference between the two leading coalitions is 49,769 votes.

The GERB-SDS coalition improved its result and received 34,734 votes more than in October last year. Now there are 669,361 people who voted for them.

Nearly 2 percent lag behind the first and second according to the results are "We Continue the Change - Democratic Bulgaria" (WCC-DB). They gathered the support of 619,592 voters, but compared to October last year, a drop of nearly 74,000 votes was reported, as the two formations then gathered the total support of 692,000 voters. If we add the percentages of the two formations from October, they are 27.6 percent, but already as a coalition they achieve a 3 percent lower result.

The third political force in yesterday's elections is the "Vazrazhdane" (Revival) party with 14.15%, followed by the Movement for Rights and Freedoms (DPS) with 13.72% and the Bulgarian Socialist Party (BSP) - with 8.94%.

"There Is Such a People" (TISP) also entered the new parliament, with the party receiving 4.11% of the vote. The trend of the "Vazrazhdane" party, which from the fourth to the third political force, is upward. Now, compared to October, it adds another 102,000 votes to its result, with 357,167 people voting for the formation yesterday.

The results for DPS, compared now and from last year, mark a drop of almost 2 thousand, and the party from third is now fourth. In October, more than 344,000 people voted for DPS, and 346,437 did so a day ago.

For BSP - fifth in terms of results, the support is also falling - from 233 thousand in October to 225 thousand now, which is minus 7 thousand votes.

103,641 voters voted for the sixth formation, which with a high degree of probability falls into the 49th National Assembly - "There Is Such a People", and in the previous elections, when Trifonov's party failed to cross the 4 percent barrier, the support was 96 thousand.

The "Bulgarian Rise" party - had 3.08% and the coalition "Levitsata!" (The Left) remain below the 4 percent barrier. - with 2.24%.

Central Election Commission data with processed 100% protocols in the Regional Election Committees of the country

In the electoral districts, the prize is for GERB SDS, which wins in 21 out of a total of 31, "We Continue the Change - Democratic Bulgaria" wins in the three capital districts, Plovdiv city and Ruse.

DPS traditionally wins in 5 districts - Kardzhali, Razgrad, Targovishte, Silistra, Shumen.

And "Vazrazhdane" is third almost everywhere.

With 100% of protocols processed abroad, the votes abroad are distributed as follows:

36.86% of all voters abroad voted for DPS, 26.67% for WCC-DB, 16.46% for "Vazrazhdane", 8.33% for GERB-SDS, 5 for TISP, 15%, and for BSP - 2.09%.

CEC data for processed 100% protocols abroad

In total, there were 122 machines that did not work for various technical reasons, and in the relevant sections, voting was only with paper ballots - this was announced by the spokesperson of the Central Election Commission, Rositsa Mateva. It has now become clear that there have been cases of the devices printing out white, blurry or shorter ballots:

"The paper that the printing house delivered to the BNB has the same requirements and characteristics as the paper used in previous elections. We will still look for the reasons and analyze why 122 machines did not work in these elections".

Mateva also said that the CEC has received reports of quite a few wrong protocols, one of the reasons being that the sectional commissions have summed up the preferential votes.

[mjordan-nba-nhl]

TOP 20 NBA PLAYERS WITH MOST POINTS AVERAGE PER GAME OF NATIONAL BASKETBALL ASSOCIATION

Michael Jordan - 30.12

Wilt Chamberlain - 30.07

Elgin Baylor - 27.36

Kevin Durant - 27.28

LeBron James - 27.21

Jerry West - 27.03

Joel Embiid - 27.02

Allen Iverson - 26.66

Bob Pettit - 26.36

George Gervin - 26.18

Oscar Robertson - 25.68

Damian Lillard - 25.16

Karl Malone - 25.02

Kobe Bryant - 24.99

Dominique Wilkins - 24.83

James Harden - 24.78

Kareem Abdul-Jabbar - 24.61

Stephen Curry - 24.54

Donovan Mitchell - 24.37

Larry Bird - 24.29

[littlefeatherr]

Tovaken 24.54 ctw Canary VS Diamond Earrings 18K

[kennak]

502 名前：可愛い奥様：2021/04/13(火) 10:26:50.50 転勤で博多に引っ越してきたんだけど九州の人って基本おとなしくて 真面目なのかしら 大阪（北摂だから治安は悪くなかったわ）と雰囲気が全然違うのよ PTA会長が男性なのにまず驚いたわ 上の子から15年間の小中学校生活でPTA会長が男性って初めてなのよ 子どもの学校関係でしてはいけないことをやらかしそうで怖くて ドキドキしてるわ 524 名前：可愛い奥様：2021/04/13(火) 10:28:24.54 >>502 大阪が明るすぎるのかもよ 557 名前：可愛い奥様：2021/04/13(火) 10:32:15.75 >>524 ほんそれよ 先生も説明会ですら笑いとりに来るし 566 名前：可愛い奥様：2021/04/13(火) 10:33:25.34 >>557 確かに大阪の日常だわ 他の地域は違うのね 541 名前：可愛い奥様：2021/04/13(火) 10:30:25.92 >>502 大阪は10代でも中身おばちゃんだもの 556 名前：可愛い奥様[] 投稿日：2021/04/13(火) 10:32:06.89 >>502 全国的にみると女性のPTA会長の方が珍しい気がするけど そうでもないのかな 567 名前：可愛い奥様：2021/04/13(火) 10:33:33.28 >>556 大阪結構自営が多いんだと思うわ 商店街のおっちゃんとかPTA会長に祭り上げられがち 607 名前：可愛い奥様：2021/04/13(火) 10:37:26.31 >>502 北摂でも他都道府県からみたら十分賑やかよ 大阪で感染者多いのは大きい声でよく喋るのも一因だと思うわ 615 名前：可愛い奥様：2021/04/13(火) 10:38:07.19 >>607 中国人み 637 名前：可愛い奥様：2021/04/13(火) 10:39:42.68 >>607 それ思うわ 小学生男児とかただでさえ超うるさいけど 大阪はそれを超えるうるささよ 653 名前：可愛い奥様：2021/04/13(火) 10:40:58.23 >>607 中国人みたいよね 661 名前：可愛い奥様：2021/04/13(火) 10:41:42.05 >>653 上海語と関西弁はイントネーションとか音が似てるらしいわよ 654 名前：可愛い奥様：2021/04/13(火) 10:41:06.48 >>607 場が沈黙なの耐えれないわ 819 名前：502：2021/04/13(火) 10:53:28.74 大阪が明るすぎるのね 確かに今までは進学指導の学年保護者会でも先生が必ず 笑いを取りにきて保護者爆笑で終わるとかだったわ 話にはネタと落ちを求める生粋の関西人のうちの子が学校で 浮いてしまわないかだけが心配よ 胃が痛くなってきたわ 828 名前：可愛い奥様：2021/04/13(火) 10:54:01.95 >>819 そのうち慣れるわよ 842 名前：可愛い奥様：2021/04/13(火) 10:54:50.43 >>819 多分うちの県だと教員から不真面目と思われそうだわ 844 名前：可愛い奥様：2021/04/13(火) 10:54:59.79 >>819 大阪ワロタwww 857 名前：可愛い奥様：2021/04/13(火) 10:56:20.85 >>819 痛切に感じるわ 能面のようにPTA会合しているわ 愛知は会の後で先生と一部の仲良しさんたちがわちゃわちゃしていたわ 860 名前：可愛い奥様：2021/04/13(火) 10:56:27.90 >>819 人気者よ大丈夫よあなたの方がやらかさないようにね 867 名前：可愛い奥様：2021/04/13(火) 10:57:06.89 >>819 大阪から転校してきた子がツッコミ激しすぎて女子のママから 苦情出てたの思い出したわw うち男子だから面白くて毎日喜んでたのに

大阪から転勤で博多に引っ越してきたんだけど九州の人って雰囲気が全然違う : 育児板拾い読み

[poonamcmi]

Bortezomib Market Estimated to Witness High Growth Owing to Rising Adoption of Proteasome Inhibitors

The bortezomib market is primarily driven by high incidence and prevalence of multiple myeloma across the globe. Bortezomib, which is commonly sold under the brand name Velcade among others, is a proteasome inhibitor primarily used for the treatment of multiple myeloma and mantle cell lymphoma.

The global proteasome inhibitor drug market size is valued at approximately US$ 24.54 million in 2024 and is expected to register a CAGR of 4.7% over the forecast period of 2024-2031. The introduction of novel proteasome inhibitors and their increasing adoption in the treatment of cancer are the major factors anticipated to propel market growth. Key Takeaways

Key players operating in the bortezomib market are Hikma Pharmaceuticals, Pfizer, Meitheal Pharmaceuticals, Novartis International AG, Bristol Myers Squibb, NATCO Pharma, Teva Pharmaceuticals, Dr. Reddy's Laboratories, Gland Pharma, Shilpa Medicare, Qilu Pharmaceutical, Scion Pharmaceuticals, Farmhispania Group, Coresyn, Chem-Stone (Guangzhou), Hubei Honch Pharmaceutical, Vinkem Labs, Icrom, TAPI Teva, and Chengdu Aslee Biopharmaceuticals.

The introduction of generic versions of Bortezomib Market Demand has led to increased adoption and lowered treatment costs. Moreover, ongoing clinical trials evaluating the efficacy of bortezomib in other cancer indications are expected to expand the eligible patient pool. Technological advancements in proteasome inhibitor development focused on overcoming resistance, reducing toxicity, and novel delivery systems are further anticipated to support market growth. Market Drivers

The primary factors driving the growth of the global bortezomib market include rising prevalence of multiple myeloma globally, increasing adoption of proteasome inhibitors in treatment regimens, availability of generic versions, and ongoing clinical research evaluating the efficacy of bortezomib in other cancer indications. Additionally, improving healthcare infrastructure and expenditures in emerging economies will further support the market growth during the forecast period. Current challenges in Bortezomib Market

The Bortezomib Market Size And Trends  faces several challenges primarily due to the presence of alternative therapeutic options for treating multiple myeloma (MM). Some of the major challenges include increasing generic competition from drugs like ixazomib and daratumumab which are leading to lower sales of bortezomib drugs. Further, the patents of bortezomib drugs have expired in several regions making them available in generic forms at lower costs. This increasing availability of low-cost generics is a major challenge faced by innovator bortezomib drug companies. Additionally, the adverse side effects associated with bortezomib drugs like neuropathy and thrombocytopenia require close patient monitoring during treatment posing operational challenges. Stringent regulations for drug approval is another regulatory challenge for new market entrants. SWOT Analysis

Strength: Well-established drug with proven efficacy and safety profile in treating MM. It was the first proteasome inhibitor approved and remains a standard of care. Weakness: Patent expiry has led to availability of low-cost generics reducing sales of innovator brands. Further, it causes serious side effects like neuropathy requiring cautious use. Opportunity: Emerging economies with growing cancer burden and healthcare spending present an opportunity. Combination therapies with other anti-MM drugs can boost its use further. Threats: Increasing competition from newer oral proteasome inhibitors and monoclonal antibody based therapies poses pricing and market share threats. Stringent regulations for approval delays market entry of new players.

Geographical regions with high market concentration

In terms of value, North America accounts for the largest share of over 40% of the global bortezomib market led by the US. This is due to established healthcare infrastructure and higher adoption of innovative therapies. Europe is the second major regional market with a value share of over 30% supported by favourable reimbursement policies. The Asia Pacific region is projected to be the fastest growing market during the forecast period due to rising healthcare expenditure, growing cancer incidence and increasing demand for cancer treatments from middle-income countries like China and India. Fastest growing geographical region

The Asia Pacific region is poised to exhibit the highest growth rate during the forecast period in the global bortezomib market. This is attributed to rising disposable incomes, growing awareness about cancer treatments, expansion of healthcare facilities and increasing private sector investment in pharmaceutical research in emerging economies like China and India. Large patient pools undergoing cancer treatment in Asia present lucrative opportunities for bortezomib drug makers looking to tap high future growth potential in this region. Get More Insights On, Bortezomib Market For More Insights Discover the Report In language that Resonates with you French, German, Italian, Russian, Chinese, Korean About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

[tamanna31]

Aptamers Market Share, Supply, Sales, Manufacturers, Competitor and Consumption 2023 to 2030

Aptamers Industry Overview

The global aptamers market size was valued at USD 1.94 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 24.54% from 2023 to 2030.

Recent advancements in the generation, purification, and drug delivery for killing target cells have attracted the attention of many researchers towards aptamers due to the competitive advantages associated with them. Some of the advantages include small molecular size, low immunogenicity, low cost of manufacturing, and lesser side effects compared to antibodies; may fuel the R&D of novel aptamers, thereby driving market growth. Despite significant efforts, there are currently no highly effective treatments available against COVID-19 infections due to a large number of genetic mutations. However, biotechnological approaches appear to be promising in the treatment of COVID-19.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Consequently, nucleic-acid based aptamers & peptide aptamers might be effective against treating COVID-19 infection. Thus, various initiatives are being undertaken by the government to boost the R&D of novel treatment for COVID-19. For instance, in September 2020, the Department of Community & Economic Development awarded a contract of USD 320,000 to Aptagen LLC for the research and development of novel treatment for the COVID-19.

The aptamers based diagnostic kits and assays developed by using SELEX technology have the ability to develop high-affinity neutralizers and bioprobes for monitoring SARS-COV-2 & COVID-19 biomarkers. Therefore, the introduction of diagnostic kits in the market for disease diagnosis is projected to drive market growth. For instance, in December 2021, Achiko AG received approval from the Ministry of Health of the Republic of Indonesia for Aptamex, a COVID-19 diagnostic kit. Aptamex is a second-generation diagnostic kit developed by using DNA aptamer-based technology that is a cost-effective, chemically synthesized, and an emerging diagnostic kit for healthcare.

Aptamers based diagnostic products are the preferred choice among diagnostic and pathology labs for the diagnosis of disease at the cellular level due to their small size, high specificity, selectivity, and efficacy. Thus, increasing prevalence of diseases such as cancer, CVD, and AMD may increase the footfall of patients in labs for the diagnosis of these diseases, consequently, increasing demand for aptamer based diagnostic products. According to Cancer Research UK estimates, around 27.5 million people are expected to be diagnosed with cancer by 2040.

In March 2022, SomaLogic announced the initiation of assaying samples using SomaScan Assay for the European Prospective Investigation into Cancer and Nutrition (EPIC) study by analyzing 210 million protein measurements from 30,000 samples. This will help researchers in predicting cancer by better understanding its nature, which in turn may contribute in market growth by addressing the increased demand.

As of now, Macugen developed by Eyetech Pharmaceuticals, Inc., (currently commercialized by Bausch Health Companies Inc.) is only the U.S. FDA approved (2004) therapeutic aptamer available in the market. It is used for the treatment of age-related muscular degeneration disorder (AMD). Technological advancements in research encourage scientists’ attention towards the development of novel aptamer based therapeutic drugs for the treatment of various diseases. Currently, there are a number of products under different clinical trials including Zimura developed by IVERIC Bio, Inc., for the treatment of patients with drug AMD. Thus, expected approval of this drug may boost the growth of the market over the period.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global structural biology & molecular modeling techniques market size was valued at USD 7.13 billion in 2023 and is projected to grow at a CAGR of 15.4% from 2024 to 2030.

• The global targeted DNA RNA sequencing market size was valued at USD 10.12 billion in 2023 and is projected to grow at a CAGR of 19.4% from 2024 to 2030.

Global Aptamers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the market trends in each of the sub-markets from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the aptamers market on the basis of type, application, and region.

Type Outlook (Revenue, USD Million; 2018 - 2030)

Nucleic Acid Aptamer

Peptide Aptamer

Application Outlook (Revenue, USD Million; 2018 - 2030)

Diagnostics

Therapeutics

Research & Development

Others

Regional Outlook (Revenue, USD Million; 2018 - 2030)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

MEA

South Africa

Saudi Arabia

UAE

Kuwait

Key Companies & Market Share Insights

Major players are adopting strategies such as modification in the existing product, approval of new products, and mergers & acquisitions for product enhancements and regional expansion to attain a greater market share. For instance, in January 2023, Aptamer Group collaborated with BaseCure Therapeutics for the development of Optimer-targeted therapies. Such initiatives can open new avenues of growth for applications of aptamers in therapeutics. Some of the prominent players in the global aptamers market include:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[plotcryptocharts]

$BTC: 60215.78 (-1.19%) $BCH: 340.0899 (-3.34%) $XRP: 0.5689 (-3.74%) $ETH: 2634.4 (0.93%) $LTC: 61.15 (0.08%) $ETC: 18.876 (-2.29%) $EOS: 0.4733 (-2.83%) $DASH: 24.54 (1.48%) $ZEC: 40.97 (0.12%) $XMR: 150.24 (0.87%) $XLM: 0.0998 (-1.13%) (2024/08/12 03:35:10)

[brr2024]

Global Freight Transport Management Market Size, Share, Trends, Drivers, Outlook, Growth And Trends

The freight transport management global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market. Freight Transport Management Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities. Market Size - The freight transport management market size has grown rapidly in recent years. It will grow from $24.54 billion in 2023 to $27.28 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%.  The  growth in the historic period can be attributed to increased globalization, growing population, increase in demand for goods and services, increase in government policies aimed at promoting global trade, rising freight transportation. The freight transport management market size is expected to see rapid growth in the next few years. It will grow to $41.18 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%.  The growth in the forecast period can be attributed to trade expansion, rise of e-commerce industry, increasing complexity of supply chains, growing demand for freight management solutions, rising transport volumes. Major trends in the forecast period include technological advancements, inclination of growth toward information technology, product innovation, investment in advanced transport management solutions, advancements in freight transport management system. Scope Of Freight Transport Management Market The Business Research Company's reports encompass a wide range of information, including: 1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth. 2. Drivers: Examination of the key factors propelling market growth. 3. Trends: Identification of emerging trends and patterns shaping the market landscape. 4. Key Segments: Breakdown of the market into its primary segments and their respective performance. 5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market. 6. Macro Economic Factors: Assessment of broader economic elements impacting the market. Market Trends - Major companies operating in the freight transport management market are developing innovative software solutions, such as transport management software, to serve customers with advanced features better. Transportation management software (TMS) is a specialized software system used by logistics and supply chain professionals to plan, execute, and optimize the transportation of goods. For instance, in December 2022, WrxFlo, an Ireland-based supply chain software provider, launched the WrxFlo Transport Management System. WrxFlo Transport Management System (TMS) is a software solution designed to assist businesses in efficiently managing the logistics of transporting physical goods, whether by land, air, or sea. This comprehensive platform enables companies to streamline operations by overseeing all transportation activities across their global supply chain. With WrxFlo TMS, haulage operators can efficiently plan, execute, and visualize logistics strategies in real-time, resulting in time savings and cost reductions.